Need help? +44 (0) 7457 418426

MEDICINE DETAILS

Zeposia

Active ingredient: Ozanimod

Neutral reference profile for an independent medicine-access consultancy enquiry about Zeposia (Ozanimod). No medicine is offered for sale.

NEXT STEP

Choose the strength and pack

✓ If you are unsure, choose “I do not know”.

These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.

ABOUT THIS MEDICINE

What is Zeposia used for?

Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of:

  • Adults with relapsing-remitting multiple sclerosis (RRMS), including:
    • Clinically isolated syndrome
    • Relapsing-remitting disease, where the patient has flare-ups (relapses) followed by periods with milder or no symptoms (remission)
    • Active secondary progressive disease
  • Adults with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).

It is available in capsule form, each containing 0.23 mg, 0.46 mg, or 0.92 mg ozanimod.

This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.

RECORDED PRODUCT PROFILE

Zeposia identity, dosage form and pack information.

The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.

Brand recordZeposia
Active ingredientOzanimod
Dosage formhard capsules
Recorded options3
Directory areaNeurology
Catalogue synchronised

Recorded strength and pack options

Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.

  1. 0.23 mg/0.46 mg · Treatment initiation pack · 7 capsules Catalogue organisation: Bristol-Myers Squibb GmbH & Co. KGaA
  2. 0.92 mg hard capsules · 28 capsules Catalogue organisation: PARANOVA PACK A/S
  3. 0.92 mg hard capsules · 98 capsules Catalogue organisation: CC Pharma GmbH

SERVICE BOUNDARY

Information checking and independent enquiry support for Zeposia.

OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.

Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.

CLEAR ANSWERS

Frequently asked questions about Zeposia

01What is Zeposia?

This directory record associates the brand name Zeposia with the active ingredient Ozanimod. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.

02Which Zeposia strengths and packs are recorded?

The catalogue currently shows: 0.23 mg/0.46 mg · Treatment initiation pack · 7 capsules; 0.92 mg hard capsules · 28 capsules; 0.92 mg hard capsules · 98 capsules. Check the complete strength, dosage form and pack description against the prescription and medicine box.

03Who manufactures Zeposia?

Catalogue records currently name: Bristol-Myers Squibb GmbH & Co. KGaA, PARANOVA PACK A/S, CC Pharma GmbH. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.

04Do the listed options confirm stock or access?

No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.

05What affects a possible estimated medicine cost for Zeposia?

A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Zeposia, payment request, stock guarantee or binding offer.

06Can I buy Zeposia from this website?

No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.